Pfizer

PFE

Market cap $155B

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

The stock is down, but the good news is that it sports a fat dividend yield of 6.4%. Pfizer has been struggling lately, but it has a rich pipeline of drugs in development.

Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.

Pfizer CEO Albert ​Bourla on ‌Monday flagged issues ​with the ​leadership of the ⁠U.S. ​Food and ​Drug Administration's vaccine department.

High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. These 3 are in the process of rerating, providing an appealing position to initiate a position.

Regencell Bioscience's outrageous performance in the past year is baffling. Despite the stock's sharp rise, there is little to look forward to for the drugmaker.

March's Large Cap Value (GASV) screen highlights 14 fair-priced, 'safer' dividend stocks, including Hafnia Ltd, IRSA Inversiones, and Weibo Corp, as actionable buys. Top ten GASV stocks are projected to deliver an average 33.21% net gain by March 2027, with risk/volatility slightly below the market average. Analyst targets indicate the five lowest-priced, highest-yield GASV stocks could outperform, with Hafnia Ltd showing a potential 42.88% gain.

Eli Lilly is the current leader in the GLP-1 weight-loss drug space. Investors have placed a high valuation on Lilly's stock.

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative.

Shifting from higher-risk assets to consistent income sources is a natural progression for retirees.